Tokyo-based Daiichi Sankyo’s ESAX-DN Phase III trial of esaxerenone met the primary endpoint in diabetic nephropathy.
Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital launched a joint laboratory to research new drugs to treat chronic lung diseases.
Omega Therapeutics debuted with a focus on epigenetics, the study of changes in gene expression that do not involve changes to the DNA sequence.
Outcome Health launched “In These Rooms” – a bespoke campaign to transform the strategy of the industry from “point of care” to “moments of care.”
Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).
British Columbia-based Chinook Therapeutics burst onto the scene with $65 million in hand and a goal of driving a portfolio of compounds aimed at kidney diseases into the clinic by 2021.
Top 200 Medicines Annual Report 2019: The king of medicines
Ankylosing Spondylitits, August 2019, Autoimmune Diseases, Biologics, Biosimilars, Blockbusters, Cervical Cancer, Classical Hodgkin Lymphoma, Crohn's Disease, Esophageal Cancer, Forecasts, Gastric Cancer, Head & Neck Cancer, Hepatocellular Carcinoma, Hidradenitis suppurativa, Issue Archives, Juvenile Idiopathic Arthritis, Market exclusivity, Melanoma, Merkel cell carcinoma, Metastatic Urothelial Carcinoma (mUC), Microsatellite instability-high (MSI-H) cancer, Monoclonal Antibodies, Non-Small Cell Lung Cancer (NSCLC), Plaque Psoriasis, Primary lediastinal large B-cell lymphoma, Product Launches, Psoriatic Arthritis, Renal Cell Carcinoma (RCC), Rheumatoid Arthritis, Therapeutics, Top 200 Medicines, Ulcerative Colitis, UveitisHumira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
Sanofi Reports Strong Second-Quarter 2019
Acquisitions, Analysts, Asthma, Atopic Dermatitis (Eczema), Business, China, Chronic Rhinosinusitis, Diabetes, Earnings per share (EPS), European Medicines Agency, FDA, Future Blockbusters, Hemophilia, Insulin, Product Launches, Profitability, Quarterly results, R&D, Relapse/Refractory Multiple Myeloma, VaccinesSanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
Havas Health & You introduced Havas ECS, a specialized strategic communications advisory and education company focused on the importance and value of foundational scientific knowledge on the endocannabinoid system,
LevLane Advertising was named agency of record by innovative health technology company Vital USA Inc.